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Abstract
Gene signatures that predict aggressive tumor behavior at the
earliest stages of disease, ideally before overt tissue abnor-
malities, are urgently needed. To search for such genes, we
generated a transgenic model of survivin, an essential
regulator of cell division and apoptosis overexpressed in
cancer. Transgenic expression of survivin in the urinary
bladder did not cause histologic abnormalities of the
urothelium. However, microarray analysis revealed that
survivin-expressing bladders exhibited profound changes in
gene expression profile affecting extracellular matrix and
inflammatory genes. Following exposure to a bladder carcin-
ogen, N-butyl-N-(4-hydroxybutyl) nitrosamine (OH-BBN), sur-
vivin transgenic animals exhibited accelerated tumor
progression, preferential incidence of tumors as compared
with premalignant lesions, and dramatically abbreviated
survival. Conversely, transgenic expression of a survivin
Thr34!Ala dominant-negative mutant did not cause changes
in gene expression or accelerated tumor progression after
OH-BBN treatment. Therefore, survivin expression induces
global transcriptional changes in the tissue microenviron-
ment that may promote tumorigenesis. Detection of survivin
or its associated gene signature may provide an early
biomarker of aggressive tumor behavior before the appear-
ance of tissue abnormalities. (Cancer Res 2005; 65(9): 3531-4)
Introduction
‘‘Molecular profiling’’ of tumors may help devise individualized
anticancer therapies (1), and identify patients that require closer
follow-up protocols (2), but gene signatures that predict clinical
course at the earliest stages of disease have not been readily
identified. A candidate tumor biomarker is survivin (3), a member of
the Inhibitor of Apoptosis (IAP) gene family (4) overexpressed in
virtually every human cancer, and implicated in protection from
apoptosis and regulation ofmitosis (3). Survivin expression has often
been linked to accelerated relapses, refractory disease, and
unfavorable outcome (3), but whether this reflects a direct
participation in tumor formation, which could be exploited as a
predictive biomarker, has remained elusive. Here, we used a
transgenic mouse model to define the role of survivin in tumor
formation, and test its relevance as a predictive biomarker. We chose
bladder cancer because survivin is a diagnostic (5) and therapeutic
(6) target in the disease, and because urothelial tumors pose
formidable challenges for patient follow-up, asf20% of seemingly
superficial lesions will progress to metastatic disease, and cause
f12,000 deaths every year in the U.S. alone (7).
Materials and Methods
Generation of survivin transgenic mice. All experiments involving
animals were approved by an Institutional Animal Care and Use Committee.
The survivin transgene was constructed by subcloning the human survivin
cDNA (wild-type or Thr34!Ala mutant; ref. 8) downstream of the murine
uroplakin II (UPII) promoter (refs. 9, 10; Fig. 1A). After purification by ion
exchange chromatography (Qiagen, Valencia, CA), and confirmation by DNA
sequencing, the constructs (200 ng/AL) were microinjected into C57BL
embryos, which were transferred into pseudopregnant females. Littermates
were screened by PCR of tail genomic DNA (11) with primers (10 pmol each)
corresponding to UPII (5V-CCTGAAAAAACCTGTCTGGGGCCCCCTCCC-3V)
and survivin (5V-GGAATTCCTCAATCCATGGCAG-3V). Colonies were main-
tained as described (11). Wild-type or p53/ breeders were purchased
from Taconic (Germantown, NY).
Gene expression profiling. Control or transgenic animals were allowed to
age without intervention for 12 or 15 months. Bladders were removed and total
RNA was isolated and processed using standard Affymetrix protocols. Samples
were processed by the Genomics Core of the University of Massachusetts
Medical School over a GeneChip Mouse Genome 430 2.0 Array. Data were
analyzed using established algorithms (GeneChip Operating Software, version
1.2, Affymetrix, Santa Clara, CA), and a cutoff of 2.2-fold difference.
Chemical carcinogenesis model. Transgenic animals or control
littermates (20 per group, 14 weeks of age) were treated weekly with
intragastric administration of N-butyl-N-(4-hydroxybutyl)nitrosamine (OH-
BBN, Tokyo Kasei Kogyo, Tokyo, Japan) for 12 weeks (12, 13). At the end of
treatment, mice were checked for development of bladder tumors and
hematuria (Henry Schein) for an additional 12 weeks. Mice that developed
palpable masses and exhibited weight loss were sacrificed. All remaining
animals were sacrificed 35 weeks after the first OH-BBN administration and
processed for histology.
Western blotting and histology. Western blotting and tissue staining
were carried out as described (14).
Statistical analysis. Data were analyzed using the unpaired t test on a
GraphPad software package for Windows (Prism). A P value of 0.05 was
considered as statistically significant.
Results and Discussion
Expression of the UPII-survivin or UPII-survivin(T34A) trans-
gene was shown by PCR (Fig. 1B), and in the urinary bladder
by immunohistochemistry (Fig. 1D and E), and Western blotting
(Fig. 1F). In contrast, nontransgenic littermates did not express
survivin in the bladder (Fig. 1C and F). UPII-survivin or UPII-
survivin(T34A) mice were grossly indistinguishable from non-
transgenic littermates, and had no histologic abnormalities of
the bladder (Fig. 1D and E). UPII-survivin mice crossed with
Note: Supplementary data for this article are available at Cancer Research Online
(http://cancerres.aacrjournals.org/).
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p53/ breeders to generate UPII-survivin-p53/+ were also
unremarkable, and these animals succumbed at 5.5 to 6 months
of age due to hematologic tumors, without macroscopic
alterations of the bladder (data not shown).
Despite the absence of histologic abnormalities, microarray
analysis of bladders of UPII-survivin animals revealed striking
changes in gene expression, as compared with nontransgenic
littermates. After removal of unknown genes, expressed sequence
tags, and low-abundance transcripts (<1 of 10 of the glyceraldehyde-
3-phosphate dehydrogenase signal), 290 genes were found modu-
lated by transgenic expression of survivin, with 102 and 188 genes
down-regulated and up-regulated, respectively (Supplementary
Table 1). Two discrete gene clusters were represented in a survivin
gene signature (Table 1). The first cluster comprised up-regulated
extracellular matrix constituents, including several collagen genes,
fibulin, vimentin, dermatopontin, fibronectin, as well as modulation
of genes controlling cell-extracellular matrix interactions, i.e.,
matrix metalloproteinase-2, small proteoglycans, connective tissue
growth factor, and h-catenin (Table 1). The second cluster con-
tained immune-inflammatory mediators, with up-regulation of
several immunoglobulin and HLA genes, complement subunits,
membrane myeloid/lymphoid antigens, cytokine and chemokine
receptors and their ligands (Table 1). Three independent
experiments validated the gene expression changes. First, using
semiquantitative reverse transcription-PCR, mRNA levels of
several randomly selected genes of the survivin gene signature
were found to be up-regulated in the bladders of UPII-survivin
mice, as compared with nontransgenic littermates (Fig. 2A).
Second, using Western blotting, increased expression of the
extracellular matrix protein fibronectin was observed in bladder
samples of UPII-survivin mice as compared with control litter-
mates (Table 1; Fig. 2B). Third, with immunohistochemistry,
bladders of UPII-survivin mice ( four of eight animals), but not
control littermates, exhibited infiltration of mononuclear cells
(Fig. 2C and D), which stained positive with an antibody to the T
cell marker CD3 (Fig. 2F and G). In contrast, UPII-survivin(T34A)
mice had no significant changes in gene expression by microarray
analysis (Supplementary Table 2), and exhibited reduced inflam-
mation of the bladder (two of eight animals, Fig. 2E).
Exposure of nontransgenic animals to OH-BBN resulted in
frank hematuria and palpable abdominal masses starting at 3
to 4 weeks after suspension of treatment. By 12 weeks after the
end of treatment, f30% of these animals exhibited abdominal
masses (Fig. 3A) and shortened survival (Fig. 3B). UPII-survivin
mice exhibited dramatic acceleration of lesion formation with
f50% of the animals presenting with abdominal masses and
hematuria within 3 weeks after the end of OH-BBN adminis-
tration (Fig. 3A). After 12 weeks, 78% of UPII-survivin mice had
abdominal tumors (Fig. 3A) and abbreviated survival (Fig. 3B).
In contrast, UPII-survivin(T34A) mice were indistinguishable
Figure 1. Characterization of survivin transgenic mice. A, survivin transgenic
constructs. (K) Kpn I, (Bx) BxtXI, (B) BamHI, (E) EcoRI. The translational
initiation codon (ATG) is indicated. B, genotyping. Genomic DNA isolated from
transgenic mice was analyzed by PCR. C-E, immunohistochemistry. Bladders
from nontransgenic (C), UPII-survivin (D), or UPII-survivin(T34A) (E) mice were
stained with an antibody to survivin. Magnification (200). F, immunoblotting.
Bladders from nontransgenic (No-TG), UPII-survivin, or UPII-survivin(T34A)
mice were analyzed by Western blotting.
Table 1. Survivin gene signature
Unigene Gene name Fold change
Mm.249555 Procollagen type III "4
Mm.271644 Fibrillin 1 "3.8
Mm.277735 Procollagen, type I a1 "3.8
Mm.130388 Procollagen type VIII, a1 "3.6
Mm.16234 Integrin a5 "3.6
Mm.10299 Procollagen type V, a2 "3.4
Mm.193099 Fibronectin "3.4
Mm.29564 Matrix metalloproteinase-2 "3.0
Mm.2608 Biglycan "2.8
Mm.258065 Laminin a4 "2.6
Mm.268000 Vimentin "2.6
Mm.297992 Fibulin 1 "2.4
Mm.28935 Dermatopontin "2.4
Mm.18888 Lumican "2.2
Mm.287146 Fibromodulin "2.2
Mm.291928 h-Catenin #3.0
Mm.1810 Connective tissue growth factor #3.0
Mm.351746 IgM Heavy chain "6.6
Mm.297582 Serum IgG2a "6.2
Mm.1192 Immunoglobulin joining chain "5.4
Mm.2923 IL2 receptor g chain "4.2
Mm.235338 Histocompatibility 2, class II
antigen Aa
"4.0
Mm.24130 CD52 "3.6
Mm.276499 Ia-associated invariant chain "3.6
Mm.10116 Chemokine (CXC) ligand 13 "3.4
Mm.45436 Lysozyme "3.2
Mm.254067 Histocompatibility 2, class II
antigen Ah1
"3.0
Mm.42029 Chemokine (CC) ligand 8 "3.0
Mm.3453 Complement component C1qg "2.6
Mm.246497 Serum IgG1 "2.4
Mm.22119 Fcg receptor IIB "2.4
Mm.2692 CD53 "2.4
NOTE: Microarray analysis was done on bladders from UPII-survivin
mice or control littermates at 12 to 15 months of age. Repre-
sentative modulated genes are shown for the two gene clusters
comprising the survivin gene signature (extracellular matrix and
inflammatory clusters).
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from nontransgenic littermates for the appearance of abdominal
masses (Fig. 3A) and survival (Fig. 3B). Histologically, control
littermates treated with OH-BBN exhibited a field of urothelial
lesions, including simple and nodular hyperplasia (9 of 15, 60%),
dysplasia (3 of 15, 20%), squamous (2 of 15, 13%), and
transitional cell carcinomas (2 of 15, 13%), often in the same
sample (Fig. 3C-E). Conversely, OH-BBN-treated UPII-survivin
animals presented a shift of urothelial lesions toward malig-
nancy with reduced hyperplasia (3 of 9, 33%), no dysplasia (0 of
9) and increased incidence of squamous (3 of 9, 33%), and
transitional (4 of 9, 44%) cell carcinomas (Fig. 3F-H). In
contrast, UPII-survivin(T34A) mice had urothelial lesions similar
to nontransgenic littermates with hyperplasia (10 of 16, 62%),
dysplasia (3 of 16, 18%), and preferential occurrence of
transitional cell carcinoma (5 of 16, 31%), as opposed to
squamous cell carcinoma (1 of 16, 6%; Fig. 3I-L).
In summary, transgenic expression of survivin in the urinary
bladder causes global changes in gene expression with up-
regulation of extracellular matrix and inflammatory genes. This
survivin gene signature was specific, i.e., transgenic expression of a
loss-of-function survivin Thr34!Ala mutant (8) had no effect, and
was phenotypically linked to aggressive tumor behavior in vivo .
Extracellular matrix genes are typically up-regulated in invasive
bladder cancer (15), as well as metastatic cancer gene signatures
(16), and inflammatory changes may promote transformation by
suppressing apoptosis in vivo (17). In this context, survivin may
contribute to tumorigenesis via inhibition of tumor cell apoptosis
(14), and changes in gene expression (this study) that favor tumor
cell invasiveness (18). Importantly, the survivin gene signature was
detected in the absence of histologic abnormalities, thus
potentially reflecting the ‘‘field’’ nature of bladder tumorigenesis
(7). Therefore, detection of survivin or its gene signature could
provide a predictive biomarker of underlying malignancy at the
earliest stages of development, and with propensity for aggressive
clinical course.
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Figure 2. Validation of survivin gene signature. A, reverse transcription-PCR.
RNA from UPII-survivin mice (T) or nontransgenic littermates (NT) was
reverse-transcribed and amplified for the indicated gene products or
glyceraldehyde-3-phosphate dehydrogenase by PCR. B, Western blotting.
Bladders of UPII-survivin mice (T) or nontransgenic littermates (NT) were
analyzed by Western blotting. C-E, histology. Bladders from UPII-survivin
(C and D ) or UPII-survivin(T34A) (E) mice were stained by H&E.
Magnifications (100, 200). F and G, immunohistochemistry. Bladders
of UPII-survivin mice exposed to OH-BBN were analyzed with an antibody
to CD3 or control IgG. Magnification (200).
Figure 3. Transgenic survivin enhances OH-BBN-induced bladder cancer.
A, onset of abdominal lesions. Nontransgenic (NT), UPII-survivin, or
UPII-survivin(T34A) mice treated with OH-BBN were monitored for palpable
abdominal masses. B, survival. The experimental conditions are as in (A),
except that animal survival was monitored after OH-BBN treatment. C-K,
histology. Tissue sections from nontransgenic (NT, C-E ), UPII-survivin (F-H ), or
UPII-survivin(T34A) (I-K ) mice were stained by H&E. The histologic diagnoses
are as follows: C, papillary hyperplasia; D, dysplasia; E, undifferentiated
carcinoma; F, transitional cell carcinoma; G, squamous cell carcinoma; H,
undifferentiated carcinoma; I, papillary metaplasia; J, transitional cell carcinoma;
K, papillary transitional cell carcinoma. Magnifications (100, 200).
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